Design and Optimization of Potent and Orally Bioavailable Tetrahydronaphthalene Raf Inhibitors
摘要:
Inhibition of mutant B-Raf signaling, through either direct inhibition of the enzyme or inhibition of MEK, the direct substrate of Raf, has been demonstrated preclinically to inhibit tumor growth. Very recently, treatment of B-Raf mutant melanoma patients with a selective B-Raf inhibitor has resulted in promising preliminary evidence of antitumor activity. This article describes the design and optimization of tetrahydronaphthalene-derived compounds as potent inhibitors of the Raf pathway in vitro and in vivo. These compounds possess good pharmacokinetic properties in rodents and inhibit B-Raf mutant tumor growth in mouse xenograft models.
DOI:
10.1021/jm101479y
作为产物:
描述:
2,5-己二酮 、 3-氨基-5-溴三氟甲苯 在
对甲苯磺酸一水合物 作用下,
以
甲苯 为溶剂,
反应 1.0h,
以to give 1-[3-bromo-5-(trifluoromethyl)phenyl]-2,5-dimethyl-1H-pyrrole (18.15 g, 98%) as orange oil的产率得到1-[3-bromo-5-(trifluoromethyl)phenyl]-2,5-dimethyl-1H-pyrrole
参考文献:
名称:
Bicyclic compounds with kinase inhibitory activity
[EN] BICYCLIC COMPOUNDS WITH KINASE INHIBITORY ACTIVITY<br/>[FR] COMPOSES BICYCLIQUES AYANT UNE ACTIVITE INHIBITRICE DE KINASE
申请人:MILLENNIUM PHARM INC
公开号:WO2007067444A1
公开(公告)日:2007-06-14
[EN] The present invention provides novel bicyclic compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases. [FR] La présente invention concerne de nouveaux composés bicycliques utiles en tant qu'inhibiteurs de protéine kinases. L'invention concerne en outre des compositions pharmaceutiques comprenant les composés de l'invention et des procédés d'utilisation des compositions dans le traitement de différentes maladies.